Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (363) 363
humans (320) 320
male (190) 190
female (186) 186
animals (162) 162
middle aged (125) 125
pharmacology & pharmacy (117) 117
drug therapy, combination (109) 109
hepatitis c, chronic - drug therapy (105) 105
macrocyclic compounds - therapeutic use (102) 102
antiviral agents - therapeutic use (98) 98
uracil - analogs & derivatives (98) 98
adult (86) 86
hepacivirus - genetics (85) 85
aged (84) 84
hepatitis c virus (84) 84
carbamates - therapeutic use (80) 80
ribavirin (80) 80
genotype (79) 79
hepatitis c (78) 78
macrocyclic compounds - administration & dosage (76) 76
anilides - therapeutic use (72) 72
analysis (70) 70
macrocyclic compounds - adverse effects (70) 70
treatment outcome (69) 69
antiviral agents - adverse effects (67) 67
antiviral agents - administration & dosage (64) 64
ritonavir - therapeutic use (63) 63
sulfonamides - therapeutic use (63) 63
hepacivirus - drug effects (60) 60
carbamates - administration & dosage (59) 59
carbamates - adverse effects (58) 58
ritonavir (56) 56
gastroenterology & hepatology (55) 55
uracil - therapeutic use (54) 54
lactams, macrocyclic - pharmacology (52) 52
article (51) 51
health aspects (51) 51
anilides - administration & dosage (50) 50
anilides - adverse effects (50) 50
hsp90 heat-shock proteins - antagonists & inhibitors (50) 50
antiviral agents (49) 49
benzoquinones - pharmacology (48) 48
drug therapy (48) 48
hepatitis (48) 48
macrocyclic compounds - pharmacology (48) 48
mice (47) 47
ribavirin - therapeutic use (47) 47
sulfonamides - administration & dosage (47) 47
hcv (46) 46
ritonavir - administration & dosage (46) 46
sulfonamides - adverse effects (46) 46
ritonavir - adverse effects (45) 45
care and treatment (44) 44
heat shock proteins (44) 44
hepatitis c - drug therapy (44) 44
oncology (44) 44
research (43) 43
abt-450/r-ombitasvir (42) 42
cancer (42) 42
dose-response relationship, drug (42) 42
interferon (42) 42
pharmacokinetics (42) 42
in-vitro (41) 41
rats (41) 41
ivermectin (40) 40
uracil - administration & dosage (40) 40
macrocyclic lactones (38) 38
uracil - adverse effects (38) 38
biochemistry & molecular biology (37) 37
hepatitis c, chronic - virology (37) 37
macrocyclic compounds - chemistry (37) 37
dasabuvir (36) 36
sustained virologic response (36) 36
therapy (36) 36
toxicology (36) 36
young adult (36) 36
liver (35) 35
drug combinations (34) 34
antineoplastic agents - pharmacology (33) 33
cell line, tumor (33) 33
hsp90 (33) 33
macrocyclic compounds (33) 33
parasitology (33) 33
cirrhosis (32) 32
medicine & public health (32) 32
sustained virological response (32) 32
chemistry, medicinal (31) 31
genetic aspects (31) 31
infections (31) 31
infection (30) 30
macrocyclic compounds - pharmacokinetics (30) 30
ombitasvir (30) 30
patients (30) 30
clinical trials (29) 29
geldanamycin (29) 29
hsp90 heat-shock proteins - metabolism (29) 29
liver cirrhosis (29) 29
proteins (29) 29
sofosbuvir (29) 29
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
by Feld, Jordan J and Kowdley, Kris V and Coakley, Eoin and Sigal, Samuel and Nelson, David R and Crawford, Darrell and Weiland, Ola and Aguilar, Humberto and Xiong, Junyuan and Pilot-Matias, Tami and DaSilva-Tillmann, Barbara and Larsen, Lois and Podsadecki, Thomas and Bernstein, Barry
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
by Bourlière, Marc and Gordon, Stuart C and Flamm, Steven L and Cooper, Curtis L and Ramji, Alnoor and Tong, Myron and Ravendhran, Natarajan and Vierling, John M and Tran, Tram T and Pianko, Stephen and Bansal, Meena B and de Lédinghen, Victor and Hyland, Robert H and Stamm, Luisa M and Dvory-Sobol, Hadas and Svarovskaia, Evguenia and Zhang, Jie and Huang, K.C and Subramanian, G. Mani and Brainard, Diana M and McHutchison, John G and Verna, Elizabeth C and Buggisch, Peter and Landis, Charles S and Younes, Ziad H and Curry, Michael P and Strasser, Simone I and Schiff, Eugene R and Reddy, K. Rajender and Manns, Michael P and Kowdley, Kris V and Zeuzem, Stefan and POLARIS-1 and POLARIS-4 Investigators and POLARIS-1 and POLARIS-4 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
In two trials involving patients with hepatitis C in whom previous treatment with direct-acting antiviral agents failed, treatment for 12 weeks with... 
GENOTYPE 1 | MEDICINE, GENERAL & INTERNAL | THERAPY | HEPATITIS-C VIRUS | EFFICACY | PROTEASE INHIBITOR GS-9857 | RESISTANCE | DIRECT-ACTING ANTIVIRALS | OPEN-LABEL | COMBINATION | PHASE-2 TRIAL | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
by Zeuzem, Stefan and Jacobson, Ira M and Baykal, Tolga and Marinho, Rui T and Poordad, Fred and Bourlière, Marc and Sulkowski, Mark S and Wedemeyer, Heiner and Tam, Edward and Desmond, Paul and Jensen, Donald M and Di Bisceglie, Adrian M and Varunok, Peter and Hassanein, Tarek and Xiong, Junyuan and Pilot-Matias, Tami and DaSilva-Tillmann, Barbara and Larsen, Lois and Podsadecki, Thomas and Bernstein, Barry
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
In this trial in patients with HCV genotype 1 infection and no cirrhosis who had previously been treated with peginterferon and ribavirin, retreatment with... 
SUSTAINED VIROLOGICAL RESPONSE | TREATMENT-NAIVE SUBJECTS | TRIAL | PEGINTERFERON/RIBAVIRIN | MEDICINE, GENERAL & INTERNAL | 3-DAY MONOTHERAPY | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | CHRONIC HEPATITIS-C | GENOTYPE 1 INFECTION | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | RNA, Viral - isolation & purification | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Retreatment | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Ritonavir | Infections | RNA polymerase | Pruritus | Patients | Ribavirin | Cirrhosis | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
by Andreone, Pietro and Colombo, Massimo G and Enejosa, Jeffrey V and Koksal, Iftihar and Ferenci, Peter and Maieron, Andreas and Müllhaupt, Beat and Horsmans, Yves and Weiland, Ola and Reesink, Henk W and Rodrigues, Lino and Hu, Yiran B and Podsadecki, Thomas and Bernstein, Barry
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
by Jacobson, Ira M and Lawitz, Eric and Gane, Edward J and Willems, Bernard E and Ruane, Peter J and Nahass, Ronald G and Borgia, Sergio M and Shafran, Stephen D and Workowski, Kimberly A and Pearlman, Brian and Hyland, Robert H and Stamm, Luisa M and Svarovskaia, Evguenia and Dvory-Sobol, Hadas and Zhu, Yanni and Subramanian, G. Mani and Brainard, Diana M and McHutchison, John G and Bräu, Norbert and Berg, Thomas and Agarwal, Kosh and Bhandari, Bal Raj and Davis, Mitchell and Feld, Jordan J and Dore, Gregory J and Stedman, Catherine A.M and Thompson, Alexander J and Asselah, Tarik and Roberts, Stuart K and Foster, Graham R
Gastroenterology, ISSN 0016-5085, 2017, Volume 153, Issue 1, pp. 113 - 122
Background & Aims Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment... 
Gastroenterology and Hepatology | Direct-Acting Antiviral Agent | Shortened Duration Therapy | Clinical Trial | Comparison | PROTEASE INHIBITOR GS-9857 | SIMEPREVIR PLUS SOFOSBUVIR | COMBINATION | CHALLENGES | GENOTYPE 1 | TREATMENT-NAIVE | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | DIRECT-ACTING ANTIVIRALS | GASTROENTEROLOGY & HEPATOLOGY | Humans | Middle Aged | Male | Carbamates - administration & dosage | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Sofosbuvir - administration & dosage | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Medical colleges | Care and treatment | Protease inhibitors | Proteases | Transplantation of organs, tissues, etc | Product development | Hepatitis C virus | Hepatitis C | Health aspects | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
by Poordad, Fred and Hezode, Christophe and Trinh, Roger and Kowdley, Kris V and Zeuzem, Stefan and Agarwal, Kosh and Shiffman, Mitchell L and Wedemeyer, Heiner and Berg, Thomas and Yoshida, Eric M and Forns, Xavier and Lovell, Sandra S and Da Silva-Tillmann, Barbara and Collins, Christine A and Campbell, Andrew L and Podsadecki, Thomas and Bernstein, Barry
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial
by Sulkowski, Mark S and Eron, Joseph J and Wyles, David and Trinh, Roger and Lalezari, Jay and Wang, Chia and Slim, Jihad and Bhatti, Laveeza and Gathe, Joseph and Ruane, Peter J and Elion, Richard and Bredeek, Fritz and Brennan, Robert and Blick, Gary and Khatri, Amit and Gibbons, Krystal and Hu, Yiran B and Fredrick, Linda and Schnell, Gretja and Pilot-Matias, Tami and Tripathi, Rakesh and Da Silva-Tillmann, Barbara and McGovern, Barbara and Campbell, Andrew L and Podsadecki, Thomas
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
IMPORTANCE: Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | VIREMIA | THERAPY | IMMUNODEFICIENCY-VIRUS INFECTION | PEGYLATED INTERFERON | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | COINFECTION | HCV | PREVALENCE | HIV-1 | Coinfection | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Ritonavir - adverse effects | Uracil - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Hepatitis C - complications | Drug Therapy, Combination | Ritonavir - administration & dosage | Treatment Outcome | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Pilot Projects | Uracil - adverse effects | Anilides - administration & dosage | Ribavirin - adverse effects | HIV Infections - complications | Sulfonamides - adverse effects | Carbamates - adverse effects | HIV Infections - drug therapy | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Drugs | Clinical trials | Hepatitis | Human immunodeficiency virus--HIV | Medical treatment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
by Ferenci, Peter and Bernstein, David and Lalezari, Jacob and Cohen, Daniel and Luo, Yan and Cooper, Curtis and Tam, Edward and Marinho, Rui T and Tsai, Naoky and Nyberg, Anders and Box, Terry D and Younes, Ziad and Enayati, Pedram and Green, Sinikka and Baruch, Yaacov and Bhandari, Bal Raj and Caruntu, Florin Alexandru and Sepe, Thomas and Chulanov, Vladimir and Janczewska, Ewa and Rizzardini, Giuliano and Gervain, Judit and Planas, Ramon and Moreno, Christophe and Hassanein, Tarek and Xie, Wangang and King, Martin and Podsadecki, Thomas and Reddy, K. Rajender and PEARL-IV Study and PEARL-III Study
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1983 - 1992
Among previously untreated patients with HCV genotype 1 infection, three new antiviral agents, with or without ribavirin, resulted in high rates of sustained... 
ANTIVIRAL AGENTS | MEDICINE, GENERAL & INTERNAL | INTERFERON | TREATMENT-NAIVE | TELAPREVIR | SOFOSBUVIR | 1 HEPATITIS-C | BOCEPREVIR | DACLATASVIR | COMBINATION | PEGINTERFERON | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Hemoglobins - analysis | Evaluation | Usage | Care and treatment | Safety and security measures | Clinical trials | Hepatitis C | Ribavirin | Headache | Ritonavir | Body weight | Fatigue | Infections | Nausea | Ribonucleic acid--RNA | Patients | Cirrhosis | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapy
by Banerjee, D and Reddy, K. R
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 03/2016, Volume 43, Issue 6, pp. 674 - 696
Summary Background Direct‐acting anti‐virals (DAAs) licensed to treat chronic HCV infection have revolutionised treatment algorithms by drastically mitigating... 
SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | ONCE-DAILY SIMEPREVIR | TREATMENT-EXPERIENCED PATIENTS | PEGYLATED INTERFERON | PHARMACOLOGY & PHARMACY | VIRUS GENOTYPE 1 | DACLATASVIR PLUS ASUNAPREVIR | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DRUG-DRUG INTERACTIONS | Isoquinolines - adverse effects | Antiviral Agents - therapeutic use | Humans | Middle Aged | Male | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Simeprevir - adverse effects | Ritonavir - adverse effects | Antiviral Agents - adverse effects | Protease Inhibitors - adverse effects | Sulfonamides - adverse effects | Female | Aged | Sofosbuvir - adverse effects | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Safety and security measures | Algorithms | Protease inhibitors | Proteases | Bilirubin | Biological response modifiers | Hepatitis C virus | Hepatitis C
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study
by Flisiak, R and Janczewska, E and Wawrzynowicz‐Syczewska, M and Jaroszewicz, J and Zarębska‐Michaluk, D and Nazzal, K and Bolewska, B and Bialkowska, J and Berak, H and Fleischer‐Stępniewska, K and Tomasiewicz, K and Karwowska, K and Rostkowska, K and Piekarska, A and Tronina, O and Madej, G and Garlicki, A and Lucejko, M and Pisula, A and Karpińska, E and Kryczka, W and Wiercińska‐Drapało, A and Mozer‐Lisewska, I and Jabłkowski, M and Horban, A and Knysz, B and Tudrujek, M and Halota, W and Simon, K
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2016, Volume 44, Issue 9, pp. 946 - 956
Summary Background Virologic and safety outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) therapy have shown high... 
SUSTAINED VIROLOGICAL RESPONSE | PLUS DASABUVIR | VIRUS-INFECTION | CIRRHOSIS | TREATMENT-EXPERIENCED PATIENTS | PHARMACOLOGY & PHARMACY | OPEN-LABEL | OMBITASVIR | GENOTYPE 1 PATIENTS | GASTROENTEROLOGY & HEPATOLOGY | HCV INFECTION | RITONAVIR | Anilides - adverse effects | Humans | Middle Aged | Male | Carbamates - administration & dosage | Diarrhea - chemically induced | Ritonavir - adverse effects | Uracil - administration & dosage | Ribavirin - administration & dosage | Adult | Drug Therapy, Combination | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Ritonavir - administration & dosage | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Uracil - adverse effects | Anilides - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Safety and security measures | Liver | Transplantation of organs, tissues, etc | Hepatitis C virus | Hepatitis C | Liver cirrhosis | Ribavirin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights